Answers are grounded in this paper and cite their sources.
Acute pancreatitis (AP) is an inflammatory condition of the pancreas with a variable clinical course, ranging from mild and self-limiting to severe and life-threatening forms, often complicated by necrosis and multiple organ failure. Despite the advances in diagnosis and treatment that have been witnessed in recent decades, the early and accurate assessment of disease severity remains a significant clinical challenge. Biomarkers play a key role in the diagnosis, risk stratification, and monitoring of AP, and they may guide the selection of appropriate therapy, including timely treatment escalation. This review discusses the pathophysiology of AP and disease severity classification in the context of biomarker use. It describes conventional prognostic tools and characterizes both established and promising novel biomarkers, ranging from routinely measured enzymes (amylase and lipase) and inflammatory markers (CRP and IL-6) to the latest molecular, genetic, and metabolomic markers. The review also presents the prospects for integrating biomarkers with artificial intelligence tools in the development of precision and personalized medicine.
No takes yet. Share an insight, caveat, or question.
Kukliński et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: